Pasithea
Therapeutics Opens its First Ketamine Therapy Clinic in the United
Kingdom
-- Pasithea Clinics partners with ZEN Healthcare – a network
of health clinics in Central London – to offer ketamine infusion
therapy for the treatment of mental health disorders --
-- Ketamine in sub-anesthetic doses has shown to be highly
effective at treating some psychiatric disorders, such as treatment
resistant depression and post-traumatic stress disorder
--
Miami Beach, FL / October 14, 2021 -- InvestorsHub NewsWire
-- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders, today announced that its wholly owned subsidiary,
Pasithea Clinics, has partnered with ZEN Healthcare to offer
intravenous ("IV") ketamine therapy to patients suffering from
treatment-resistant mental health issues. Initially, the treatment
will be offered in Knightsbridge, London, beginning October
2021.
Pasithea Therapeutics
recently raised $24 million at its initial public offering
("IPO"). The Company's Common Stock began trading on The Nasdaq
Capital Market on September 15, 2021, under the symbol
"KTTA."
Pasithea Clinics has clinic partnerships both in the
United States and in the United Kingdom to provide IV ketamine
treatment. In the U.K., it has partnered with ZEN
Healthcare – a network of health clinics in London. In the U.S., it
has partnered with The IV Doc, Inc., to provide in-home IV ketamine
infusions. Both partnerships offer rapid exposure and
expansion opportunities.
"With mental health cases on the rise, fueled even more so by
the pandemic, new treatment therapies are urgently needed for those
patients who are not responding to traditional treatments. Evidence
from dozens of trials over the past two decades consistently
supports the efficacy of ketamine in improving symptoms in some
mental health disorders. We are thrilled to be able to provide this
new treatment approach in the U.K. for those patients who are
deemed eligible to receive it," stated Dr. Tiago Reis Marques, CEO
of Pasithea Therapeutics.
"This launch marks a significant milestone for Pasithea
Clinics and for patients in the U.K. suffering with mental health
conditions. We look forward to growing our specialty clinics
network while we simultaneously progress with our drug development
program to move the needle forward for better mental health care,"
concluded Dr. Reis Marques.
"This is an
exciting opportunity for Pasithea Clinics to offer ground-breaking
therapies to those who can really benefit. Our highly
trained professionals are taking an integrative approach that
combines the IV ketamine infusion therapy with psychiatric support.
Today, there is still much misunderstanding about ketamine and its
application in a psychiatric setting, but the potentially rapid and
potent antidepressant effects are beginning to be recognized within
the regulatory and scientific communities. People struggling with their mental
health ultimately deserve to explore every avenue to recovery
without social stigmas. We believe we can become the
best-in-class provider of IV ketamine treatments,"
said Dr. Yassine
Bendiabdallah, Managing Director of
Pasithea Clinics in the UK.
Ketamine is a U.S. Food and Drug Administration ("FDA")
approved drug introduced to the medical community as an anesthetic
more than 50 years ago. It has recently been repurposed for the treatment of
psychiatric disorders using significantly lower doses than in
anesthesia and is now gaining ground as a promising
treatment for mental health disorders. In certain psychiatric conditions, such as
treatment-resistant depression ("TRD") and post-traumatic stress
disorder ("PTSD"), it has shown remarkable efficacy and a rapid and
sustained effect.
Major Depression is the leading cause of long-term disability
worldwide, according to the World Health Organization, with
existing treatments having limited success rates, numerous side
effects and onset of action delayed by several weeks. Studies have
shown that with IV ketamine treatment, up to 70% of those who
receive this treatment can eventually show a clinical response.
While the number of treatments suggested is done on a case-by-case
basis, a typical treatment plan
consists of up to six infusions in the interval of two to three
weeks.
About Pasithea
Therapeutics Corp.
Pasithea Therapeutics
Corporation is a U.S. biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders. With an experienced team of experts in the
fields of neuroscience and psychopharmacology, Pasithea is
developing new molecular entities for the treatment of psychiatric
and neurological disorders. Pasithea is also focused on addressing
the needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
About ZEN
Healthcare
ZEN Healthcare is a luxury
pharmacy and health clinic in London with three branches – Baker
Street, Knightsbridge and Holborn. The clinics comprise a
multidisciplinary group of Private GPs, anti-ageing doctors,
pharmacists, nutritionists, dermatologists and psychotherapists, as
well as intravenous infusions specialists. ZEN Healthcare has been
running pioneering IV therapies in London for six years.
Forward
Looking Statements
This press release contains statements that constitute
"forward-looking statements." Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company's filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis
Marques
Chief Executive
Officer
E:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M.
Wilson
In-Site
Communications, Inc.
T:
212-452-2793
E:
lwilson@insitecony.com